No Data
No Data
sino biopharm (01177.HK): The study data of the combination of CUMOXIL capsules with FLUVASTATIN injection for the treatment of endocrine-treated HR+/HER2- advanced breast cancer stage III will be released by CSCO in 2024.
Grants Link News September 27th: Sino Biopharm (01177.HK) announced that the Group's Class 1 innovative drug Kymriah capsules has been orally presented at the 2024 National Clinical Oncology Association Conference (2024 CSCO) with the latest research results of Phase III clinical trial (TQB3616-III-01), used in combination with Fluvisumab Injection for the treatment of endocrine-treated Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) advanced breast cancer: median progression-free survival (PFS) is 16.62 months, objective response rate (ORR).
中國生物製藥:二零二四年中期報告
sino biopharm (01177.HK): "Lisdexamfetamine transdermal patch" approved for listing.
Grace 25th, Sino Biopharm (01177.HK) announced that the group's developed "Rivastigmine Transdermal Patch" (brand name: Debaitai) has obtained the market approval from China's National Medical Products Administration for the treatment of mild to moderate Alzheimer's disease symptoms. This is the first domestically approved Rivastigmine Transdermal Patch. According to the disclosure, Rivastigmine is a cholinesterase inhibitor used to treat Alzheimer's disease. Acetylcholine is an important neurotransmitter that transmits information between neurons and plays a key role in brain regions related to memory and learning. Rivastigmine works by inhibiting acetylcholine.
Express News | Sino Biopharmaceutical - Approval for Marketing of "Rivastigmine Transdermal Patch" by Nmpa
Sino Biopharm (01177.HK): The Phase III study data of anlotinib hydrochloride capsules combined with bemcentinib injection for first-line treatment of advanced renal cell carcinoma will be announced at ESMO 2024.
Sino Biopharm (01177.HK) announced on September 16th that the group's Type 1 innovative drug Anlotinib Hydrochloride Capsules combined with Bevacizumab Injection has released the latest results of Phase III clinical trial (ETER100) in the form of a small oral report at the European Society for Medical Oncology (ESMO 2024) Annual Meeting. It is used for the first-line treatment of advanced renal cell carcinoma (RCC): the median progression-free survival (PFS) is 18.96 months, the objective response rate (ORR) is 71.6%, and the overall survival (OS) is obtained.
Increased support for innovative drugs, the collective rise of the innovative drug sector, sino biopharm (01177) rose 4.5%.
Jingu Finance News | The innovative drug sector as a whole is on the rise, with Lai Kai Medicine (02105) up 6.07%, Sino Biopharm (01177) up 4.5%, Genscript Bio (01548) up 4.07%, Hutchmed (China) (00013) up 2.68%, and Innovent Bio (01801) up 2.1%. The State Council Information Office held a series of themed press conferences on 'Promoting High-Quality Development', and Li Li, Director of the National Medical Products Administration, stated at the conference the increased support for pharmaceutical R&D innovation. This includes the evaluation and approval, inspection and verification of innovative drugs and medical instruments that are key to the country's support.
No Data
No Data